PV Bulletin

Swissmedic Guidance on Injectable Products for Wrinkle Treatment

Updated guidance clarifying the classification and professional use requirements for injectable aesthetic products, such as botulinum toxin and dermal fillers.

Primary source: Swissmedic

PV Impact Brief

Urgency: HighConfidence: high

What changed

Botulinum toxin is now confirmed as prescription-only, and strict safety and professional use requirements for dermal fillers are mandated under the MedDO.

Why it matters

These changes necessitate healthcare professionals to adhere to new reporting and compliance measures concerning injectable products, ultimately aiming to enhance patient safety.

Action needed

Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.

Relevant for
Regulatory Intelligence LeadQPPV
Processes impacted
Country Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Guidance
Policy status
final
Publication date
June 19, 2026
Policy change
Updated guidance clarifying the regulatory classification and professional use requirements for injectable aesthetic products, such as botulinum toxin and dermal fillers.

Key changes

Confirms botulinum toxin as prescription-only; mandates strict safety and professional use requirements for dermal fillers under MedDO.

Affected workflows

Country Compliance

Responsible groups

MAHsMedical Affairs

PV impact

Reinforces risk management and safety monitoring for aesthetic medicinal products and devices.

View regulator source

Source document details

Exact policy details

Version
4.0
Applies to: Applicable to the information sheet on injectable products for wrinkle treatment.
Document version stated on page 1. · p. 1 · High · Source
Valid from
19.06.2026
Applies to: Date from which the version of the document is effective.
Effective date noted on page 1. · p. 1 · High · Source
Authorization Requirement for Injectable Products
Botulinum toxin must be authorized as medicinal products.
Applies to: Applies to all injectable products classified as medicinal products.
Stated on page 3 regarding botulinum toxin preparations. · p. 3 · High · Source
Conformity Assessment Requirement
Products containing hyaluronic acid, along with others, must undergo a conformity assessment procedure.
Applies to: Applicable to injectable products regulated by the Medical Devices Ordinance.
Highlighted on page 4 and page 6. · p. 4 · High · Source
Reporting Obligation
Healthcare professionals must report all serious incidents involving the use of such devices to Swissmedic.
Applies to: Mandatory for users of injectable devices.
Noted on page 5 under Art. 66 para. 4 MedDO. · p. 5 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 19, 2026

Full briefing

Practical implication

Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.

The updated information sheet from Swissmedic specifies that botulinum toxin is classified as a prescription-only medicinal product, while dermal fillers are subject to safety and professional use requirements as per the Medical Devices Ordinance (MedDO). It emphasizes mandatory risk management and safety monitoring for these aesthetic products.

What changed: Botulinum toxin is now confirmed as prescription-only, and strict safety and professional use requirements for dermal fillers are mandated under the MedDO.

Why it matters: These changes necessitate healthcare professionals to adhere to new reporting and compliance measures concerning injectable products, ultimately aiming to enhance patient safety.

Practical implication: Healthcare professionals must report all serious incidents involving injectable devices to Swissmedic as outlined in the new guidance.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#final#policy-change#guidance#firecrawl-policy-agent#Swissmedic

Related updates for your role

publicEuropean Medicines Agency · European Union · Updated Aug 19, 2026

Updated Companion Diagnostics Consultation Procedure by EMA

Urgency: High

Notified Bodies and medical device manufacturers should adhere to the updated requirement of using the IRIS platform for notification and submission processes concerning companion diagnostics, ensuring compliance with the new timelines and submission methods.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Q&A
Read impact briefarrow_forward
publicTherapeutic Goods Administration (TGA) · Australia · Updated Aug 19, 2026

Enforcement action disrupts illicit vape distribution network in Sydney

Urgency: High

Ongoing investigations into unlawful vaping products are expected to result in further enforcement actions, including additional seizures and potential penalties for non-compliance with the Therapeutic Goods Act.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicTGA · Australia · Updated Aug 17, 2026

TGA seizes illegal peptides and steroids linked to social media influencer

Urgency: High

Regulatory intelligence workflows should address this enforcement action as part of ongoing compliance monitoring regarding the sale and promotion of unapproved therapeutic goods.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · United Kingdom · Updated Aug 18, 2026

MHRA Clarifies Regulatory Pathways for Microbiome-Based Medicinal Products

Urgency: High

Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.

Literature SurveillanceCountry ComplianceRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Notice / Position Paper
Read impact briefarrow_forward